MX384144B - Composiciones y métodos para el tratamiento del cáncer. - Google Patents

Composiciones y métodos para el tratamiento del cáncer.

Info

Publication number
MX384144B
MX384144B MX2019000279A MX2019000279A MX384144B MX 384144 B MX384144 B MX 384144B MX 2019000279 A MX2019000279 A MX 2019000279A MX 2019000279 A MX2019000279 A MX 2019000279A MX 384144 B MX384144 B MX 384144B
Authority
MX
Mexico
Prior art keywords
formula
cancer
treatment
compositions
methods
Prior art date
Application number
MX2019000279A
Other languages
English (en)
Other versions
MX2019000279A (es
Inventor
Mahesh Kandula
Original Assignee
Cellix Bio Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Private Ltd filed Critical Cellix Bio Private Ltd
Publication of MX2019000279A publication Critical patent/MX2019000279A/es
Publication of MX384144B publication Critical patent/MX384144B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a los compuestos o polimorfos, solvatos, enantiómeros, estereoisómeros e hidratos farmacéuticamente aceptables de los mismos. Las composiciones farmacéuticas que comprenden una cantidad eficaz de los compuestos de la Fórmula I, Fórmula II, Fórmula III, Fórmula IV, Fórmula V, Fórmula VI, Fórmula VII y Fórmula VIII y, los métodos para el tratamiento del cáncer y enfermedades infecciosas pueden formularse para administración oral, bucal, rectal, tópica, transdérmica, transmucosa, gragea, aerosol, intravenosa, solución oral, tableta de capa de mucosa bucal, administración parenteral, jarabe o inyección. Dichas composiciones pueden usarse para el tratamiento del cáncer, neoplasias, infecciones y enfermedades de la piel.
MX2019000279A 2016-06-28 2017-05-12 Composiciones y métodos para el tratamiento del cáncer. MX384144B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201641022026 2016-06-28
IN201641025259 2016-07-22
IN201741006185 2017-02-21
PCT/IB2017/052814 WO2018002739A1 (en) 2016-06-28 2017-05-12 Compositions and methods for the treatment of cancer

Publications (2)

Publication Number Publication Date
MX2019000279A MX2019000279A (es) 2019-08-01
MX384144B true MX384144B (es) 2025-03-14

Family

ID=60785109

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000279A MX384144B (es) 2016-06-28 2017-05-12 Composiciones y métodos para el tratamiento del cáncer.

Country Status (14)

Country Link
US (2) US10858349B2 (es)
EP (1) EP3452044A4 (es)
JP (1) JP6950972B2 (es)
KR (1) KR102306412B1 (es)
CN (1) CN109414438A (es)
AU (3) AU2017286852B2 (es)
BR (1) BR112018076257A2 (es)
CA (1) CA3027118C (es)
IL (2) IL263563A (es)
MX (1) MX384144B (es)
RU (1) RU2770081C2 (es)
SG (1) SG11201810947PA (es)
WO (1) WO2018002739A1 (es)
ZA (1) ZA201808232B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202100411TA (en) * 2018-08-03 2021-02-25 Cellix Bio Private Ltd Compositions and methods for the treatment of cancer
EP3679952A1 (en) * 2019-01-10 2020-07-15 Université de Strasbourg Nanoemulsions encapsulating prodrugs
EP4153137A4 (en) * 2020-05-19 2024-07-10 Cellix Bio Private Limited PHARMACEUTICAL FORMULATIONS AND THEIR MANUFACTURE FOR THE TREATMENT OF CANCER
WO2022043902A1 (en) * 2020-08-29 2022-03-03 Cellix Bio Private Limited Process for the preparation of derivatives of 5-fluoro pyrimidines used as anti cancer agents
WO2022049462A1 (en) * 2020-09-05 2022-03-10 Cellix Bio Private Limited Process for the preparation of derivatives of 5-fluoro pyrimidines used as anti cancer agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
TW254946B (es) * 1992-12-18 1995-08-21 Hoffmann La Roche
JPH1192386A (ja) * 1997-09-17 1999-04-06 Nikken Chem Co Ltd ５−フルオロウリジン誘導体を有効成分とする抗癌剤
EP1311524A2 (en) * 2000-08-09 2003-05-21 Kolon Industries, Inc. 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients
KR20110042204A (ko) * 2008-08-01 2011-04-25 다우 아그로사이언시즈 엘엘씨 살진균제로서의 5-플루오로시토신의 용도
EP2393472B1 (en) * 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
US10463684B2 (en) * 2014-01-29 2019-11-05 Board Of Regents, The Uneversety Of Texas System Nucleobase analogue derivatives and their applications
GB201419015D0 (en) * 2014-10-24 2014-12-10 Orca Pharmaceuticals Ltd Compounds

Also Published As

Publication number Publication date
BR112018076257A2 (pt) 2019-03-26
US20190292171A1 (en) 2019-09-26
IL280587B (en) 2021-10-31
RU2019100713A (ru) 2020-07-28
ZA201808232B (en) 2019-09-25
IL263563A (en) 2019-01-31
JP2019519563A (ja) 2019-07-11
RU2770081C2 (ru) 2022-04-14
AU2023208158A1 (en) 2023-08-17
AU2021203748A1 (en) 2021-07-08
CA3027118C (en) 2023-08-15
KR20190034539A (ko) 2019-04-02
SG11201810947PA (en) 2019-01-30
AU2017286852A1 (en) 2019-01-17
EP3452044A1 (en) 2019-03-13
EP3452044A4 (en) 2020-04-22
IL280587A (en) 2021-03-25
AU2017286852B2 (en) 2021-05-06
US10858349B2 (en) 2020-12-08
CN109414438A (zh) 2019-03-01
RU2019100713A3 (es) 2021-02-08
MX2019000279A (es) 2019-08-01
CA3027118A1 (en) 2018-01-04
KR102306412B1 (ko) 2021-09-28
NZ749512A (en) 2021-08-27
JP6950972B2 (ja) 2021-10-20
US20210078983A1 (en) 2021-03-18
WO2018002739A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
MX379545B (es) Composiciones y metodos para el tratamiento del dolor cronico.
MX386467B (es) Composiciones y métodos para el tratamiento de xerostomia (sequedad bucal)
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
MX384144B (es) Composiciones y métodos para el tratamiento del cáncer.
CO2019011809A2 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
MX382331B (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina útiles en el tratamiento del cáncer.
CU20160109A7 (es) Compuestos de indazol como inhibidores de irak4
CY1119727T1 (el) Ενωσεις και συνθεσεις για τη θεραπεια παρασιτικων νοσων
SV2018005750A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue
CY1120826T1 (el) Τριυποκατεστημενα παραγωγα βενζοτριαζολης ως αναστολεις διϋδροοροτικης οξυγενασης
MD20160106A2 (ro) Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4
MX2017009449A (es) Inhibidor jak.
WO2013175377A3 (en) Compositions and methods for treatment of mucositis
MX2022005523A (es) Composiciones y metodos para el tratamiento de infecciones fungicas.
MX382175B (es) Composiciones de profármaco de monometilfumarato
WO2013175376A3 (en) Compositions and methods for the treatment of local pain
BR112016024235A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
MX388592B (es) Compuestos y metodos terapeuticos.
MX381129B (es) Inhibidores de dopamina-b-hidroxilasa.
WO2016046680A3 (en) Compositions and methods for the treatment of liver metabolic diseases
MX383090B (es) Composiciones y métodos para el tratamiento de enfermedades infecciosas orales.
MX386902B (es) Metodos para el tratamiento de trastornos cardiovasculares.
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
MX386208B (es) Composiciones y métodos para el tratamiento de pólipos gastrointestinales.